[go: up one dir, main page]

EP4180816A3 - Immunological solid phase assay with spatially resolved signal (sfida) for quantification of at least 2 protein aggregates - Google Patents

Immunological solid phase assay with spatially resolved signal (sfida) for quantification of at least 2 protein aggregates Download PDF

Info

Publication number
EP4180816A3
EP4180816A3 EP22200832.8A EP22200832A EP4180816A3 EP 4180816 A3 EP4180816 A3 EP 4180816A3 EP 22200832 A EP22200832 A EP 22200832A EP 4180816 A3 EP4180816 A3 EP 4180816A3
Authority
EP
European Patent Office
Prior art keywords
quantification
sfida
solid phase
spatially resolved
protein aggregates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP22200832.8A
Other languages
German (de)
French (fr)
Other versions
EP4180816A2 (en
Inventor
Dieter Willbold
Eva Birkmann
Kateryna KRAVCHENKO
Aileen FUNKE
Oliver BANNACH
Steffen HÜBINGER
Carsten Korth
Verian Bader
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forschungszentrum Juelich GmbH
Original Assignee
Forschungszentrum Juelich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forschungszentrum Juelich GmbH filed Critical Forschungszentrum Juelich GmbH
Publication of EP4180816A2 publication Critical patent/EP4180816A2/en
Publication of EP4180816A3 publication Critical patent/EP4180816A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/645—Specially adapted constructive features of fluorimeters
    • G01N21/6456—Spatial resolved fluorescence measurements; Imaging
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/645—Specially adapted constructive features of fluorimeters
    • G01N21/6456—Spatial resolved fluorescence measurements; Imaging
    • G01N21/6458—Fluorescence microscopy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G01N2333/936—Hydrolases (3) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetyl-amino 2-deoxy-D-glucose, e.g. lysozyme
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Die Erfindung betrifft ein Verfahren zur Ermittlung von Indikatoren zur Bestimmung von Krankheiten (Krankheitsindikatoren), in denen Aggregate fehlgefalteter Proteine eine Rolle spielen, sowie ein Verfahren zur selektiven Quantifizierung und/oder Charakterisierung dieser Krankheitsindikatoren.The invention relates to a method for determining indicators for determining diseases (disease indicators) in which aggregates of misfolded proteins play a role, and a method for the selective quantification and/or characterization of these disease indicators.

EP22200832.8A 2013-06-26 2014-06-25 Immunological solid phase assay with spatially resolved signal (sfida) for quantification of at least 2 protein aggregates Withdrawn EP4180816A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102013106713.1A DE102013106713A1 (en) 2013-06-26 2013-06-26 Method for identifying indicators for the determination of diseases
EP14752793.1A EP3014279B1 (en) 2013-06-26 2014-06-25 Method for determining protein aggregates using surface-fida
PCT/EP2014/063418 WO2014207049A2 (en) 2013-06-26 2014-06-25 Method for detecting indicators for determining diseases

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP14752793.1A Division EP3014279B1 (en) 2013-06-26 2014-06-25 Method for determining protein aggregates using surface-fida

Publications (2)

Publication Number Publication Date
EP4180816A2 EP4180816A2 (en) 2023-05-17
EP4180816A3 true EP4180816A3 (en) 2023-07-26

Family

ID=51359355

Family Applications (3)

Application Number Title Priority Date Filing Date
EP22200832.8A Withdrawn EP4180816A3 (en) 2013-06-26 2014-06-25 Immunological solid phase assay with spatially resolved signal (sfida) for quantification of at least 2 protein aggregates
EP22200826.0A Withdrawn EP4180815A3 (en) 2013-06-26 2014-06-25 Immunological solid phase assay with spatially resolved signal (sfida) for quantification of at least 2 protein aggregates
EP14752793.1A Active EP3014279B1 (en) 2013-06-26 2014-06-25 Method for determining protein aggregates using surface-fida

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP22200826.0A Withdrawn EP4180815A3 (en) 2013-06-26 2014-06-25 Immunological solid phase assay with spatially resolved signal (sfida) for quantification of at least 2 protein aggregates
EP14752793.1A Active EP3014279B1 (en) 2013-06-26 2014-06-25 Method for determining protein aggregates using surface-fida

Country Status (9)

Country Link
US (1) US11175288B2 (en)
EP (3) EP4180816A3 (en)
JP (1) JP6478987B2 (en)
CN (1) CN105358978A (en)
DE (1) DE102013106713A1 (en)
DK (1) DK3014279T3 (en)
ES (1) ES2935060T3 (en)
FI (1) FI3014279T3 (en)
WO (1) WO2014207049A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102015003404B4 (en) * 2015-03-18 2021-10-07 Forschungszentrum Jülich GmbH Process for the production of a standard for the detection of protein aggregates of a protein misfolding disease and standard and its use
DE102016121455A1 (en) * 2016-11-09 2018-05-09 Forschungszentrum Jülich GmbH Ultrasensitive detection of virus and virus-like particles
EP3583124A1 (en) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
CN110831669B (en) * 2017-03-07 2024-11-19 匹兹堡大学联邦高等教育系统 Optogenetic induction of neurodegenerative disease pathology
JP6886854B2 (en) * 2017-04-13 2021-06-16 シスメックス株式会社 Information acquisition method for test substances
DE102017010455A1 (en) * 2017-06-13 2018-12-13 Forschungszentrum Jülich GmbH Method for detecting aggregates of biotherapeutic substances in a sample
JP2020148598A (en) * 2019-03-13 2020-09-17 株式会社Ｊｖｃケンウッド Method for manufacturing analytical substrate
JP2020148599A (en) * 2019-03-13 2020-09-17 株式会社Ｊｖｃケンウッド Analytical board and analytical unit
WO2020184377A1 (en) * 2019-03-13 2020-09-17 株式会社Ｊｖｃケンウッド Method for fabricating analysis substrate, analysis substrate, and analysis unit
DE102020003794A1 (en) * 2020-06-25 2021-12-30 Forschungszentrum Jülich GmbH Method, use of the method and kit for the detection of bioindicators in a sample
CN113008850B (en) * 2021-02-07 2022-02-25 首都医科大学宣武医院 Application of diagnosing Alzheimer disease and device for diagnosing Alzheimer disease
JP2025137899A (en) * 2022-06-28 2025-09-25 大塚製薬株式会社 Methods for determining synucleinopathy
CN115266663B (en) * 2022-06-30 2023-06-16 四川省医学科学院·四川省人民医院 Biological probe for non-invasive diagnosis of parkinsonism triggered by intestinal microenvironment as well as preparation method and application thereof
WO2025099457A2 (en) * 2023-11-10 2025-05-15 Cambridge Enterprise Limited Novel method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080038761A1 (en) * 2006-01-30 2008-02-14 Invitrogen Corporation Compositions and methods for detecting and quantifying toxic substances in disease states
WO2008070229A2 (en) * 2006-08-28 2008-06-12 Case Western Reserve University Detection of pathogenic aggregates of protein in a sample by homologous elisa
US20090042211A1 (en) * 2005-07-04 2009-02-12 Eva Birkmann Method for the Selective Detection of Pathological Protein Depositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0884583A1 (en) * 1997-06-10 1998-12-16 Evotec BioSystems GmbH A method for characterizing samples in at least two dimensional space of specific physical properties
WO2005018424A2 (en) * 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
EP1848817B1 (en) * 2005-02-19 2013-04-24 Peoplebio, Inc. Method for differentially detecting multimeric form from monomeric form of multimer-forming polypeptides
DE102006010647A1 (en) * 2006-03-06 2007-09-13 Latza, Reinhard, Dr.med. Test for the detection of pathological prions
WO2007126473A2 (en) * 2006-04-10 2007-11-08 Oligomerix, Inc. Oligomerization of amyloid proteins
WO2008140639A2 (en) * 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarkers and assays for alzheimer's disease
DE202007003085U1 (en) 2007-03-02 2007-05-24 BSH Bosch und Siemens Hausgeräte GmbH Plastic moulded outer drum for a horizontal axis front loading washing machine has a horizontal outlet in the lower region directed to the side into which the pressure chamber is fitted
WO2010003227A1 (en) * 2008-07-08 2010-01-14 Amorfix Life Sciences Ltd. Detection of protein aggregates
MX2012008840A (en) * 2010-02-09 2012-09-07 Squibb Bristol Myers Co Immunoassay standards and measurement of clinical biomarkers using intra-assay calibration standards.
DE102011057019A1 (en) * 2011-12-23 2013-06-27 Forschungszentrum Jülich GmbH Standard for the quantification of pathogenic aggregates from endogenous proteins
DE102011057021A1 (en) 2011-12-23 2013-06-27 Forschungszentrum Jülich GmbH Method for the selective quantification of A-beta aggregates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090042211A1 (en) * 2005-07-04 2009-02-12 Eva Birkmann Method for the Selective Detection of Pathological Protein Depositions
US20080038761A1 (en) * 2006-01-30 2008-02-14 Invitrogen Corporation Compositions and methods for detecting and quantifying toxic substances in disease states
WO2008070229A2 (en) * 2006-08-28 2008-06-12 Case Western Reserve University Detection of pathogenic aggregates of protein in a sample by homologous elisa

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FUNKE ET AL: "Single particle detection of Abeta aggregates associated with Alzheimer's disease", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 364, no. 4, 24 October 2007 (2007-10-24), pages 902 - 907, XP022344209, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2007.10.085 *
PILAR INFIESTA ET AL: "Development of an assay to measure tau oligomer levels in AD", 42ND ANNUAL MEETING OF THE SOCIETY-FOR-NEUROSCIENCE; NEW ORLEANS, LA, USA, 17 October 2012 (2012-10-17), XP055147762, Retrieved from the Internet <URL:http://www.oligomerix.com/frames/tech/Oligomerix%20Tau%20Biomarker%20Poster%20for%20SfN%202012%20-%20FINAL.pdf> [retrieved on 20141020] *
SUSANNE AILEEN FUNKE ET AL: "An Ultrasensitive Assay for Diagnosis of Alzheimer's Disease", REJUVENATION RESEARCH, vol. 11, no. 2, 1 April 2008 (2008-04-01), pages 315 - 318, XP055060114, ISSN: 1549-1684, DOI: 10.1089/rej.2008.0670 *
SUSANNE AILEEN FUNKE ET AL: "Single-Particle Detection System for Ab Aggregates: Adaptation of Surface-Fluorescence Intensity Distribution Analysis to Laser Scanning Microscopy", REJUVENATION RESEARCH, vol. 13, no. 2-3, 4 December 2009 (2009-12-04), pages 206 - 209, XP055060118, DOI: 10.1089=rej.2009.0925 *
WANG-DIETRICHET: "The amyloid-beta oligomer count in cerebrospinal fluid is a biomarker for Alzheimer's disease", JOURNAL OF ALZHEIMER'S DISEASE, vol. 34, 11 January 2013 (2013-01-11), pages 985 - 994, XP055060188 *

Also Published As

Publication number Publication date
DE102013106713A1 (en) 2014-12-31
JP6478987B2 (en) 2019-03-06
FI3014279T3 (en) 2023-01-13
EP4180815A2 (en) 2023-05-17
EP3014279B1 (en) 2022-10-12
US20160161481A1 (en) 2016-06-09
EP3014279A2 (en) 2016-05-04
WO2014207049A3 (en) 2015-09-17
WO2014207049A2 (en) 2014-12-31
ES2935060T3 (en) 2023-03-01
EP4180816A2 (en) 2023-05-17
EP4180815A3 (en) 2023-11-01
CN105358978A (en) 2016-02-24
JP2016524151A (en) 2016-08-12
DK3014279T3 (en) 2023-01-09
US11175288B2 (en) 2021-11-16

Similar Documents

Publication Publication Date Title
EP4180816A3 (en) Immunological solid phase assay with spatially resolved signal (sfida) for quantification of at least 2 protein aggregates
CY1120390T1 (en) COMPOSITION AND METHOD FOR DIAGNOSIS AND TREATMENT OF DISEASES RELATING TO NURSES
BR112014028785A2 (en) st2 antigen binding proteins
CL2018001089A1 (en) Valbenazine salts and polymorphs thereof.
BR112018073761A2 (en) single chain variable fragment cd3 binding proteins
WO2015176066A3 (en) Lpa-associated protein and rna expression
AR092818A1 (en) HUMANIZED TAU ANTIBODY
HK1258444A1 (en) Anti-wt1/hla-specific antibodies
EA201790438A1 (en) ANTIGEN-BINDING PROTEINS THAT CONNECT WITH CXCR5
PH12019500596A1 (en) Recombinant binding proteins and their use
BR112018000768A2 (en) anti-pd-1 antibodies, activatable anti-pd-1 antibodies and methods of use
MX2017003269A (en) Detection of misfolded proteins.
MA41313A (en) MODIFIED APRIL PROTEIN BINDING ANTIBODIES
ECSP13012402A (en) IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND ITS USE
UA123202C2 (en) ANTIBODY TO TAU-PROTEIN AND ITS APPLICATION
PH12017500032B1 (en) Improved a㟠protofibril binding antibodies
WO2017015619A8 (en) Antibodies to coagulation factor xia and uses thereof
EP3661527A4 (en) ADAPTED MULTIBIOMARKER DISEASE ACTIVITY SCORE FOR THE EVALUATION OF INFLAMMATORY DISEASES
EP3710836A4 (en) Protein biomarker indicators of neurological injury and/or disease and methods of use thereof
WO2015117088A3 (en) Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein tdp-43
CN104853774A8 (en) IL-20 antagonists for the treatment of liver diseases
MX2022010954A (en) Device for detecting misfolded proteins and methods of use therof.
EP3470847A3 (en) Standard for quantification of pathogenic aggregates comprising body proteins
WO2016014612A3 (en) Compositions and methods for the diagnosis of rheumatoid arthritis
HK1225298A1 (en) Use of a cd6 binding partner and method based thereon

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221011

AC Divisional application: reference to earlier application

Ref document number: 3014279

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 21/64 20060101ALI20230620BHEP

Ipc: G01N 33/543 20060101ALI20230620BHEP

Ipc: G01N 33/68 20060101AFI20230620BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240127